- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06582901
Interventions for Clinical High Risk Youth in Tunisia (CHRTUNISIA)
Cognitive Training vs. Treatment as Usual to Improve Functioning and Reduce Transition Rates in Tunisian CHR Youth: A Feasibility Study
Study Overview
Status
Conditions
Detailed Description
RESEARCH STRATEGY Recruitment of Study Participants Potential study participants are help-seeking youth recruited through the network of trained mental health professionals at schools and universities of the Greater Tunis area (see above) as well as through the CHiRP network at the outpatient departments of Razi University Hospital and Mongi Slim University Hospital.
Randomization to Cognitive Training (CT-NEAR) vs. Enhanced Treatment as Usual (E-TAU) After study entry, patients will be randomized to Cognitive Training (CT-NEAR) or Enhanced Treatment as Usual (E-TAU) using a 1:1 randomization immediately after completion of the baseline assessment battery. Both treatments will last 3 months. Participants in the two conditions will receive treatment which will be carefully tracked and all medication types and doses recorded. The conditions will be matched on all key variables such as amount of therapist and in-clinic time by offering group activities for participants in the E-TAU condition. A clinical and neurocognitive assessment battery will be administered to all participants at baseline by masked assessors. The clinical assessments (symptoms and functioning) will be repeated at 6 weeks (mid-point), and the full assessment battery will be repeated at the 3-month conclusion of the randomized treatment. We will examine the effects of the treatment on neurocognitive functioning, conversion, and role and social functioning.
Cognitive Training Using the Neuropsychological Education Approach to Remediation (CT-NEAR) Enhanced Treatment as Usual Comparison Group The E-TAU condition will consist of regular contact with mental health professionals in the outpatient clinic which involves conducting and monitoring of psychosocial interventions such as Cognitive Behavior Therapy groups for depression and anxiety, case management, supportive counselling, a psychoeducation group, and watching films at home for 30 minutes on a tablet. None of these interventions target improvement in cognition. Participants in the E-TAU condition will receive all of the baseline and follow-up clinical and neurocognitive assessments. The E-TAU condition will be matched for therapist time, group interaction time, and the use of a tablet at home. After the 3-month E-TAU period, participants will be offered participation in the cognitive training and will of course not be included in the CT-NEAR study sample.
Implementation of the Intervention Alignment with National Institute of Mental Health (NIMH) Strategic Plan: The current proposal aligns with several components of the NIMH Strategic Plan 2020.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Joseph Ventura, Ph.D.
- Phone Number: 310-245-2811
- Email: jventura@mednet.ucla.edu
Study Locations
-
-
-
Tunis, Tunisia
- Recruiting
- Razi University Hospital
-
Contact:
- Uta Ouali, M.D.
- Phone Number: +216 716 00 154
- Email: uta.ouali@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Meets Comprehensive Assessment for At Risk Mental States (CAARMS) criteria for Clinical High Risk
- If under the age of 18, the subject has a parent or guardian who can sign consent forms
- Premorbid Intelligence Quotient not less than 70
- Sufficient fluency in Arabic, French, or English to avoid invalidating research measures
- Residence likely within commuting distance of Razi University Hospital
Exclusion Criteria:
- Evidence of known neurological disorder, e.g. epilepsy or significant head injury that could account for the CHR symptoms
- Evidence of significant and habitual alcohol or substance use in the 6 months prior to study entry
- Evidence that the clinical high-risk symptoms were substance-induced
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Enhanced Treatment as Usual
Enhanced Treatment as Usual (E-TAU) sessions are delivered in a group therapy format and guided by the principles of Cognitive Behavioral Therapy (CBT).
The E-TAU sessions focus on helping individuals identify and change negative thought patterns and behaviors that contribute to emotional distress and mental health issues.
|
The Enhanced-Treatment as Usual (E-TAU) sessions are delivered in a group therapy format and guided by the principles of Cognitive Behavioral Therapy (CBT).
Participants learn to develop coping skills and are educated on how to improve distortions to reduce anxiety and depression.
|
|
Experimental: Cognitive Training
Computer Based Cognitive Training (CT) Programs delivered in a group setting using the Neuropsychological Educational Approach to Cognitive Remediation (NEAR) model.
|
Psychosocial interactions computer-based cognitive training (CT) administered in a group setting that includes the Neuropsychological Educational Approach to Cognitive Remediation (NEAR) model:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Cognitive Functioning
Time Frame: Baseline, 3 months
|
Neurocognitive Test Battery.
Scored on a composite of various cognitive tests will indicate improved, not improved at follow-up.
The composite score ranges from 0 to 50 with higher scores indicating greater improvement.
|
Baseline, 3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Global Functioning Scale - Role and Social
Time Frame: Baseline, 3 months
|
Interview-based assessment of work or school functioning and of social functioning.
Scores range from 0-100 with higher score indicating better functioning.
|
Baseline, 3 months
|
|
Comprehensive Assessment of At-Risk Mental States
Time Frame: Baseline, 3 months
|
Interview based assessment of clinical status assess change in clinical status from baseline to post - intervention.
The scores range from 0-60 with higher scores indicating worse outcomes.
|
Baseline, 3 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Joseph Ventura, Ph.D., UCLA Department of Psychiatry & Biobehavioral Sciences
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Stress, Psychological
- Prodromal Symptoms
- Investigative Techniques
- Therapeutics
- Patient Care
- Health Services
- Health Care Facilities Workforce and Services
- Rehabilitation
- Aftercare
- Continuity of Patient Care
- Neurological Rehabilitation
- Models, Theoretical
- Cognitive Training
- Models, Biological
Other Study ID Numbers
- IRB#23-001029
- R21MH131319 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Clinical High Risk for Psychosis (CHR)
-
Monument Therapeutics LimitedNational Institute of Mental Health (NIMH); Foundation for the National Institutes... and other collaboratorsRecruitingClinical High Risk for Psychosis (CHR)United States
-
University of OxfordWellcome Trust; Jazz PharmaceuticalsNot yet recruitingClinical High Risk for Psychosis | Clinical High Risk for Psychosis (CHR) | Clinical High Risk for Developing PsychosisUnited Kingdom, Italy, Greece, Finland, Germany, Netherlands, Austria, Canada, Spain, Switzerland
-
Centre Psychothérapique de NancyRecruitingClinical High Risk for Psychosis (CHR)France
-
Centre for Addiction and Mental HealthNot yet recruitingClinical High Risk for Psychosis (CHR)Canada
-
New York State Psychiatric InstituteNational Institute of Mental Health (NIMH); Stony Brook Medicine; Columbia University... and other collaboratorsNot yet recruitingClinical High Risk for Psychosis (CHR)
-
Icahn School of Medicine at Mount SinaiNational Institute of Mental Health (NIMH)RecruitingClinical High Risk for Psychosis (CHR)United States
-
Centre Psychothérapique de NancyRecruitingClinical High Risk for Psychosis (CHR)France
-
University of Alabama at BirminghamNot yet recruitingSchizophrenia | Clinical High Risk for Psychosis (CHR)United States
-
Icahn School of Medicine at Mount SinaiNational Institute of Mental Health (NIMH)Enrolling by invitationFirst Episode Psychosis (FEP) | Clinical High Risk for Psychosis (CHR)United States
-
Centre Psychothérapique de NancyNot yet recruitingClinical High Risk for Psychosis (CHR)France
Clinical Trials on Cognitive training (CT) plus the neuropsychological educational approach to cognitive remediation (NEAR) model and an Enhanced - Treatment as Usual (E-TAU)
-
Mental Health Services in the Capital Region, DenmarkCopenhagen Trial Unit, Center for Clinical Intervention Research; Center for...CompletedPatients at Ultra-high Risk of PsychosisDenmark